Why Is Hims & Hers Health (HIMS) Stock Moving Today?

Hims & Hers Health (HIMS) is a telehealth platform offering treatments for sexual health, hair loss, mental health, and weight loss. Its stock is driven by subscriber growth, average order value, the GLP-1 weight loss compounding business, and FDA regulatory decisions on compounded medications.

What causes HIMS to move?

• GLP-1 compounding revenue: Hims & Hers began offering compounded semaglutide (generic Ozempic/Wegovy) at lower prices during the drug shortage period. This became a massive revenue driver - and FDA decisions on compounding eligibility are the biggest HIMS catalyst.
• FDA compounding decisions: The FDA determines whether brand-name GLP-1 drugs are in shortage (allowing compounding) or not. Declarations ending shortage status threaten Hims's GLP-1 business and trigger large stock drops.
• Subscriber growth: Online subscriber count across all categories (sexual health, hair, weight, mental health) signals platform health and multi-product adoption.
• Average order value (AOV): Higher AOV reflects customers adopting multiple treatment categories or premium products - a key ARPU expansion signal.
• Eli Lilly and Novo Nordisk competition: The branded GLP-1 manufacturers (Lilly's Zepbound, Novo's Wegovy) compete directly and have pushed to end the compounding period. Any supply normalization reduces Hims's price advantage.
• Personalized medicine narrative: Hims positions customized compounded GLP-1 formulations as a premium product even post-shortage. Regulatory acceptance of personalized dosing is a key upside catalyst.

ExplainThisMove gives you the reasons behind Hims & Hers Health's recent stock movement in real time: the catalyst, the news, and the technical context. Also explore: SOFI, AMZN, SPY.

Frequently asked questions

What does HIMS stand for?

HIMS is the stock ticker symbol for Hims & Hers Health. This page tracks why HIMS is moving and what is driving it today.

Why is HIMS going up or down today?

HIMS can move on earnings, guidance, analyst upgrades or downgrades, news catalysts, sector rotation, and broad market or macro shifts. For the specific reason HIMS is up or down right now, enter HIMS into ExplainThisMove above.

Why did HIMS stock go up today?

HIMS rises on strong subscriber growth, GLP-1 compounding revenue beats, FDA decisions extending compounding eligibility, new treatment category launches, or raised full-year guidance. Type HIMS into ExplainThisMove for today's catalyst.

Why did HIMS stock drop today?

HIMS falls sharply when the FDA declares GLP-1 drug shortages resolved (ending compounding eligibility), on subscriber growth misses, when Lilly or Novo improve drug supply, or on regulatory warnings about compounded weight-loss drugs.

How does GLP-1 compounding affect Hims stock?

Hims & Hers offered compounded semaglutide at roughly $200/month vs $1,300+ for branded Wegovy. During the FDA shortage designation, this was legal and drove explosive revenue growth. The FDA's decision to end the shortage designation in 2025 was a major negative catalyst, as it threatened this high-growth revenue stream.

Is Hims & Hers just a GLP-1 company now?

No, but GLP-1 became Hims's largest revenue segment very quickly. The company also has established profitable businesses in men's sexual health (ED, hair loss) and women's health. Management frames its long-term strategy as personalized health - but near-term, GLP-1 regulatory outcomes dominate the stock narrative.